Loading market dashboard
Marvel Biosciences Corp.
MRVL.VHealthcareTSXVCA
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
Marvell Technology, Inc. (NASDAQ: MRVL - Get Free Report)'s stock price rose 2.1% during mid-day trading on Monday after B. Riley Financial raised their price target on the stock from $135.00 to $156.00. B. Riley Financial currently has a buy rating on the stock. Marvell Technology traded as high as $133.20 and last traded at $131.1810.
Hager Investment Management Services LLC lessened its stake in Marvell Technology, Inc. (NASDAQ: MRVL) by 27.6% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 18,001 shares of the semiconductor company's stock after selling 6,859 shares during the quarter.
Marvell Technology, Inc. (NASDAQ: MRVL - Get Free Report) COO Chris Koopmans sold 10,000 shares of the company's stock in a transaction dated Monday, April 6th. The shares were sold at an average price of $110.24, for a total transaction of $1,102,400.00. Following the sale, the chief operating officer owned 133,870 shares in the company, valued
Marvell Technology, Inc. (NASDAQ: MRVL - Get Free Report) EVP Mark Casper sold 6,900 shares of the business's stock in a transaction dated Monday, April 6th. The shares were sold at an average price of $109.45, for a total value of $755,205.00. Following the completion of the sale, the executive vice president owned 10,263 shares in
